Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Circulation. 1990;81:369-380

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Farber, N. E.
Right arrow Articles by Gross, G. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Farber, N. E.
Right arrow Articles by Gross, G. J.

Circulation, Vol 81, 369-380, Copyright © 1990 by American Heart Association


ARTICLES

Prostaglandin redirection by thromboxane synthetase inhibition. Attenuation of myocardial stunning in canine heart

NE Farber and GJ Gross
Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee 53226.

We have previously reported that inhibition of thromboxane synthesis results in an improvement in postischemic function in stunned myocardium of dogs. The purpose of the present study was to investigate further the mechanism by which thromboxane synthesis inhibition improves recovery of function in stunned myocardium (15 minutes of coronary occlusion and 3 hours of reperfusion) in barbital anesthetized dogs. The recovery of regional myocardial wall function (percent segment shortening, % SS) following treatment with two doses (0.5 and 10 mg/kg) of a thromboxane receptor blocker, BM 13.505, given prior to coronary occlusion, was not different from that of a control group (3- hour % SS of pretreatment control, PTC, 12 +/- 11) throughout reperfusion (3-hour % SS of PTC with BM 13.505: 0.5 mg/kg 14 +/- 10; 10 mg/kg, 27 +/- 9). In contrast, the specific thromboxane synthetase inhibitor, dazmegrel (3.0 mg/kg), significantly improved % SS throughout reperfusion (3-hour % SS of PTC, 66 +/- 8). In addition, while dazmegrel produced a marked decrease in thromboxane, 6-keto-PGF1 alpha was significantly increased in coronary venous blood throughout the occlusion and reperfusion period. The cyclooxygenase inhibitor, indomethacin, had no beneficial effect on functional recovery (3-hour % SS of PTC, 5 +/- 6), attenuated the dazmegrel induced shunting to prostacyclin, and completely prevented the beneficial effects of dazmegrel on functional recovery (3-hour % SS of PTC, 17 +/- 12). Thus, a redirection to endogenous cardioprotective prostanoids, such as prostacyclin, appears to be responsible for the beneficial effect of thromboxane synthesis inhibition on postischemic recovery in stunned myocardium whereas thromboxane does not appear to be an important mediator of the stunning phenomenon.


This article has been cited by other articles:


Home page
Cardiovasc ResHome page
G. J. Gross, J. R. Falck, E. R. Gross, M. Isbell, J. Moore, and K. Nithipatikom
Cytochrome P450 and arachidonic acid metabolites: Role in myocardial ischemia/reperfusion injury revisited
Cardiovasc Res, October 1, 2005; 68(1): 18 - 25.
[Abstract] [Full Text] [PDF]


Home page
Anesth. Analg.Home page
C. R. McCrory and S. G. E. Lindahl
Cyclooxygenase Inhibition for Postoperative Analgesia
Anesth. Analg., July 1, 2002; 95(1): 169 - 176.
[Full Text] [PDF]


Home page
CLIN APPL THROMB HEMOSTHome page
V. L. Serebruany, V. V. Yurovsky, and P. A. Gurbel
Mild Myocardial Stunning Affects Platelet Aggregation and Certain Hemostatic Factors in Swine
Clinical and Applied Thrombosis/Hemostasis, October 1, 1999; 5(4): 236 - 242.
[Abstract] [PDF]


Home page
J. Thorac. Cardiovasc. Surg.Home page
B. L. Robinson, T. Morita, K. Fujita, M. Chow, H. V. Schaff, and J. J. Morris
BYPASS CONDUIT VESSEL WALL BIOLOGY SUBSTANTIALLY INFLUENCES DOWNSTREAM MYOCARDIAL CONTRACTILE RESPONSE TO INJURY FROM ISCHEMIA AND REPERFUSION
J. Thorac. Cardiovasc. Surg., January 1, 1996; 111(1): 62 - 73.
[Abstract] [Full Text]